| Literature DB >> 24578682 |
Guido Wassink1, Eleanor R Gunn1, Paul P Drury1, Laura Bennet1, Alistair J Gunn1.
Abstract
Acute post-asphyxial encephalopathy occurring around the time of birth remains a major cause of death and disability. The recent seminal insight that allows active neuroprotective treatment is that even after profound asphyxia (the "primary" phase), many brain cells show initial recovery from the insult during a short "latent" phase, typically lasting approximately 6 h, only to die hours to days later after a "secondary" deterioration characterized by seizures, cytotoxic edema, and progressive failure of cerebral oxidative metabolism. Although many of these secondary processes are potentially injurious, they appear to be primarily epiphenomena of the "execution" phase of cell death. Animal and human studies designed around this conceptual framework have shown that moderate cerebral hypothermia initiated as early as possible but before the onset of secondary deterioration, and continued for a sufficient duration to allow the secondary deterioration to resolve, has been associated with potent, long-lasting neuroprotection. Recent clinical trials show that while therapeutic hypothermia significantly reduces morbidity and mortality, many babies still die or survive with disabilities. The challenge for the future is to find ways of improving the effectiveness of treatment. In this review, we will dissect the known mechanisms of hypoxic-ischemic brain injury in relation to the known effects of hypothermic neuroprotection.Entities:
Keywords: asphyxia; encephalopathy; hypothermia; injury; neuroprotection
Year: 2014 PMID: 24578682 PMCID: PMC3936504 DOI: 10.3389/fnins.2014.00040
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Figure 1The effects of 30 min of cerebral ischemia (from The top panel shows changes in extradural (solid circles) and esophageal (solid squares) temperature in the hypothermia group and extradural (open circles) and esophageal (open squares) temperature in the normothermia group. The lower two panels show changes in EEG intensity (dB) and cortical impedance (expressed as percentage of baseline) in the hypothermia (solid circles) and normothermia (open circles) groups. The hypothermia group showed greater recovery of EEG intensity after resolution of delayed seizures and complete suppression of the secondary rise in impedance. Data modified from Gunn et al. (1998). *p <0.05; **p <0.001.
Figure 2Schematic diagram illustrating the different pathological phases of cerebral injury after severe hypoxic-ischemia. OFRs, oxygen free radicals; BBB, blood brain barrier; EAAs, excitatory amino acids; NO, nitric oxide.
Figure 3Flow chart depicting several intracellular mechanisms associated with permeabilization of the mitochondrial membranes, leading to progressive failure of mitochondrial oxidative phosphorylation and ultimately delayed programmed cell death. Upstream triggers such as inflammation and trophic withdrawal activate cell surface death receptors initiating the “extrinsic” pathway to programmed cell death. Conversely, calcium overload and oxygen free radicals appear to exert their effect predominantly at the mitochondrial level via the “intrinsic” pathway. In addition, cross-over activation between the “extrinsic” and “intrinsic” pathway may take place through pro-apoptotic intermediates such as the BID protein. AIF, apoptosis inducing factor. Apaf-1, apoptotic protease-activating factor−1; ATP, adenosine triphosphate; BAK, Bcl2-antagonist/killer 1; BAX, Bcl2-associated × protein; Bcl2, B-cell lymphoma 2 protein family; Bcl-X, B-cell lymphoma-extra-large; BID, BH3 interacting-domain death agonist; Diablo, direct inhibitor of apoptosis binding protein with low Pi; P53, p53 tumor suppressor protein; Smac, Second mitochondria-derived activator of caspase; tBID, truncated BH3 interacting-domain death agonist; TNF, tumor necrosis factor receptor; TRAIL, TNF-related apoptosis-inducing ligand receptor.